1 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine , Hopkins Bayview Medical Center, Baltimore, Maryland.
2 San Francisco Department of Public Health , San Francisco, California.
AIDS Patient Care STDS. 2018 Jul;32(7):288-296. doi: 10.1089/apc.2018.0014. Epub 2018 Jun 8.
This secondary analysis compares health behavior outcomes for two groups of HIV+ substance users randomized in a 3-arm trial [1] to receive Patient Navigation with (PN+CM) or without (PN) contingent financial incentives (CM). Mean age of participants was 45 years; the majority was male (67%), African American (78%), unemployed (35%), or disabled (50%). Behaviors incentivized for PN+CM were (1) attendance at HIV care visits and (2) verification of an active HIV medication prescription. Incentives were associated with shorter time to treatment initiation and higher rates of behaviors during the 6-month intervention with exception of month 6 HIV care visits. Median HIV care visits were 3 (IQR 2-4) for PN+CM versus 1.5 (IQR 0-3) for PN (Wilcoxon p < 0.001); median validated medication checks were 4 (IQR 2-6) for PN+CM versus 1 (IQR 0-3) for PN (Wilcoxon p < 0.001). Viral suppression rates at end of treatment were not significantly different for the two groups but were directly related to the number of behaviors completed for both care visits (χ(1) = 7.69, p = 0.006) and validated medication (χ(1) = 8.49, p = 0.004). Results support use of incentives to increase performance of key healthcare behaviors. Adjustments to the incentive program may be needed to achieve greater rates of sustained health behavior change that result in improved viral load outcomes.
本二次分析比较了在一项 3 臂试验中随机分配接受患者导航(PN)加(CM)或不(PN)条件性财务激励的两组 HIV+物质使用者的健康行为结果[1]。参与者的平均年龄为 45 岁;大多数为男性(67%)、非裔美国人(78%)、失业(35%)或残疾(50%)。PN+CM 激励的行为是(1)参加 HIV 护理就诊和(2)验证有效的 HIV 药物处方。激励措施与治疗开始时间缩短和 6 个月干预期间行为发生率更高相关,但 6 个月的 HIV 护理就诊除外。PN+CM 的中位数 HIV 护理就诊次数为 3(IQR 2-4),PN 的中位数为 1.5(IQR 0-3)(Wilcoxon p < 0.001);PN+CM 的中位数经验证的药物检查次数为 4(IQR 2-6),PN 的中位数为 1(IQR 0-3)(Wilcoxon p < 0.001)。治疗结束时病毒抑制率在两组间无显著差异,但与完成的行为数量直接相关,包括护理就诊(χ(1) = 7.69,p = 0.006)和验证药物(χ(1) = 8.49,p = 0.004)。结果支持使用激励措施来增加关键医疗行为的表现。可能需要对激励计划进行调整,以实现更高的持续健康行为改变率,从而改善病毒载量结果。